TWiV 941: Clinical update with Dr. Daniel Griffin
In his weekly clinical update Dr. Griffin discusses\xa0increased acute respiratory illnesses among children and adolescents,\xa0estimates of monkeypox incubation period, generation time, and reproduction number, rapid increase in suspected SARS-CoV-2 reinfections, interim infection prevention and control recommendations for healthcare personnel during COVID-19, SARS-CoV-2 secondary attack rates in vaccinated and unvaccinated household contacts during replacement of delta with omicron variant,\xa0breakthrough infection by SARS-CoV-2 delta and omicron variants elicited immune response comparable to mRNA booster vaccination,\xa0interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses,\xa0further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants,\xa0short-course early outpatient Remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the Omicron BA.2 wave,\xa0effectiveness of Molnupiravir in high risk patients,\xa0and primary care and a distinct symptom pattern for long COVID.
Subscribe (free):\xa0Apple Podcasts,\xa0Google Podcasts,\xa0RSS,\xa0email
Become a\xa0patron\xa0of\xa0TWiV!
Links for this episode- Research assistant position with Amy Rosenfeld (pdf)
- Support MicrobeTV with a Spike t-shirt at Vaccinated.US
- Increase in Acute Respiratory\xa0illnesses among children and adolescents (CDC)
- Estimates of\xa0Monkeypox incubation period, generation time, reproduction number (CDC)
- Rapid increase in suspected\xa0SARS-CoV-2\xa0reinfections (CDC)
- Infection prevention and control recommendations for\xa0healthcare providers\xa0(CDC)
- SARS-CoV-2 attack rate\xa0in vaccinated and unvaccinated household contacts (CDC)
- Breakthrough Infection by variants elicited immune response\xa0comparable to vaccine\xa0(JID)
- Interval between\xa0prior SARS-CoV-2 infection\xa0and booster vaccination impacts (CELL)
- Humoral immunity evasion of\xa0BA.4 and BA.5\xa0subvariants (The Lancet)
- Outpatient Remdesivir\xa0prevents severe disease in organ transplant recipients (Am J Transplant)\xa0
- PAXLOVID patient eligibility\xa0screening checklist (FDA)
- Remdesivir fact sheet\xa0for providers (Veklury)\xa0
- Bebtelovimab fact sheet\xa0for providers (FDA)
- Effectiveness of Molnupiravir in\xa0high risk patients\xa0(CID)
- Update on\xa0Long COVID\xa0for primary care (BMJ)
- Distinct symptom pattern\xa0emerges for COVID-19 long-haul (Scientific Reports)
- Dr. Griffin\u2019s treatment guide (pdf)
- Contribute to\xa0Floating Doctors fundraiser at PWB
- Letters read\xa0on TWiV 941
- Timestamps by Jolene. Thanks!
Intro music is by\xa0Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv